Why Enliven Therapeutics, Inc.’s (ELVN) Stock Is Down 5.02%
As of Wednesday, August 05, Enliven Therapeutics, Inc.’s ELVN share price has dipped by 5.02%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Commentary & Analysis
Why Enliven Therapeutics, Inc.’s (ELVN) Stock Is Up 5.13%
As of Tuesday, June 23, Enliven Therapeutics, Inc.’s ELVN share price has surged by 5.13%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Enliven Therapeutics, Inc.’s (ELVN) Stock Is Up 5.50%
As of Monday, June 22, Enliven Therapeutics, Inc.’s ELVN share price has surged by 5.50%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Enliven Therapeutics, Inc.’s (ELVN) Stock Is Up 6.28%
As of Wednesday, May 13, Enliven Therapeutics, Inc.’s ELVN share price has surged by 6.28%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Enliven Therapeutics, Inc.’s (ELVN) Stock Is Up 7.20%
As of Tuesday, May 12, Enliven Therapeutics, Inc.’s ELVN share price has surged by 7.20%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ELVN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,309.8 | $587.7 | 64% |
|
| Shares Out (Mil) | 66.2 | 44.5 | 54% |
|
| Institutional Ownership | 96.9% | 84.6% | 72% |
|
| Float (Mil) | 64.5 | 46.8 | 53% |
|
| Beta | 0.24 | 0.69 | 15% |
|
| Avg Daily Volume (000s) | 1,332 | 361 | 74% |
|
| Price Change (52-week) |
194.3% | 66.7% | 97% |
|
| Growth | ELVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (40.4%) | (1.4%) | 9% |
|
| EPS (5yr) | 13.6% | 14.9% | 53 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (14.9%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 4 | |
| Current EPS | ($0.477) | ($1.967) | ($2.295) | |
| Month Ago EPS | ($0.433) | ($1.695) | ($2.325) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.480) | ($1.825) | ($2.383) | |
| Year/Year Chg | (2.9%) | 7.5% | 62.3% | |
| Financials | ELVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $276 | na |
|
| Net Income (TTM) (Mil) | ($106) | ($11) | 11% |
|
| EPS (TTM) | ($1.672) | ($0.700) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($67) | ($6) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $16 | $5 | 61% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 17% |
|
| Enterprise Value (Q1) (Mil) | $3,536 | $309 | 58% |
|
| Valuation | ELVN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.81 | 2.89 | 76% |
|
| P/E | na | 17.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ELVN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.5% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (15.0%) | (22.5%) | 22% |
|
| ROE | (15.3%) | (19.8%) | 25% |
|
| Liabilities to Assets | 1.7% | 32.4% | 1% |
|
| F-Score | 3 | 3 | 18% |
|
Enliven Therapeutics, Inc. did not pass any screens on 8/14/2026.
